Pricing Log in Create free account
Friday 6 November 2026 Export GOSS’s income statement to Excel — free account

Gossamer Bio, Inc.

GOSS Healthcare Biotechnology

Gossamer Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $48.5 million, down 57.7% from fiscal 2024.

Revenue
−19.6%
EPS
+129.4%
Free cash flow
+16.3%
Total debt
−81.7%

Quarter to June 2026, against a year earlier

9.75 0.33 +3.50%
Market cap
$57.6M
P/E
0.0×
Fwd P/E
−0.6×
Dividend yield
—
F-score
n/a
Altman Z
−12.52
Beneish M
0.74
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Size
Market Cap 57.56
Revenue ttm 53.29
Net income ttm (125.22)
Free cash flow ttm (162.63)
Net debt Q (20.88)
Valuation
P/E 0.00
Forward P/E (0.63) (negative: loss-making)
Price / sales 0.73
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.00
Financial health
Current ratio Q 0.53 (below 1: weak)
Debt / equity Q (0.38) (negative: negative equity)
Interest coverage Q (9.64)
Growth
Revenue growth Q −19.59% (below 0%: shrinking)
Operating income growth Q +32.74% (above 0%: growing)
EPS, this year +73.96% (at or above 15%: strong)
EPS, next year A +32.65% (at or above 15%: strong)
Revenue, next year A −16.42% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +45.71% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 296 295 137 57
Receivables — 5 12 6
Inventory — — — —
Other — — — —
307 310 168 73
2023 2024 2025 Q'26
Payables 6 2 6 6
ST’ Debt 12 — — 36
Other — 17 20 68
52 45 63 138

Compound Annual Growth %

10y 5y 3y
Sales — — —
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 0.00% 0.00%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −8.00 Actual −16.00

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −15.20 −16.80 Miss by 1.60
Q4 FY25 −16.00 −16.80 Miss by 0.80
Q1 FY26 −13.60 −16.00 Miss by 2.40
Q2 FY26 −8.00 −16.00 Miss by 8.00
Q3 FY26 −5.55 — Reports 4 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (16.00) 4.11 — — —
’25 (12.80) (13.60) (16.80) (16.80) (60.00)
’24 (15.20) 17.60 (11.20) (12.00) (20.00)
’23 (41.60) (36.00) (16.80) (16.95) (94.40)
’22 (60.80) (59.20) (52.00) (47.20) (216.80)
’21 (62.40) (64.00) (64.00) (59.20) (250.40)
’20 (69.60) (80.00) (64.00) (70.40) (284.00)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 17 9 — — —
’25 10 11 13 14 48
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (39) (39) — — —
’25 (40) (47) (36) (48) (171)
’24 (52) 116 (32) (35) (3)
’23 (53) (38) (34) (33) (159)
’22 (53) (49) (37) (48) (187)
’21 (59) (47) (42) (41) (189)
’20 (52) (42) (45) (37) (176)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (39) (39) — — —
’25 (40) (47) (36) (48) (171)
’24 (52) 116 (32) (35) (3)
’23 (53) (38) (34) (33) (159)
’22 (54) (49) (37) (48) (187)
’21 (60) (48) (43) (41) (190)
’20 (53) (43) (45) (37) (178)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — — — — — — — 115 48 53 (57.7%) 41 17 71 +13.4%
Gross margin, % — — 0.00 0.00 0.00 0.00 0.00 — 100.00 100.00 100.00 +100.0 pt
EBT 0 (7) (147) (180) (243) (234) (229) (180) (56) (170) (125) n/m
EBT margin, % 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 (48.50) (351.67) (235.17) (351.7) pt
Net income 0 (7) (147) (180) (243) (234) (229) (180) (57) (170) (125) +133.4%
Per share, $
Per share, $ Revenue 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 40.56 16.97 13.32 n/m
Earnings 0.00 (59.13) (1,807.20) (263.20) (284.00) (250.40) (216.80) (94.40) (20.00) (60.00) (45.60) n/m
Cash flow 0.00 (50.17) (627.85) (211.65) (205.93) (201.91) (176.91) (83.42) (1.23) (59.96) (40.65) n/m
Capex 0.00 0.00 (42.93) (4.33) (1.75) (1.65) (0.39) 0.00 0.00 (0.03) 0.00 n/m
Free cash flow 0.00 (50.17) (670.77) (215.99) (207.69) (203.57) (177.30) (83.42) (1.23) (59.98) (40.65) n/m
Book value 0.00 (59.93) (1,476.86) 515.10 374.46 129.84 11.42 32.90 10.43 (42.98) (23.51) n/m
Shares, m 66 0 0 1 1 1 1 2 3 3 3 (29.4%)
Valuation, ×
Valuation, × P/E — — — — — — — — 0.00 0.00 0.00 0.0
P/S — — — — — — — — 0.00 14.62 0.73 7.3
P/B — — — — — — — — 6.94 0.00 0.00 3.5
EV/Sales — — — — — — — — 0.00 16.08 4.07 8.0
EV/FCF — — — — — — — — (30.23) (4.55) (1.33) (17.4)
Cash, $m
Cash, $m Operating cash flow 0 (6) (51) (145) (176) (189) (187) (159) (3) (171) (163) n/m
Capex — — (3) (3) (2) (2) 0 — — 0 0 (41.8%)
Free cash flow 0 (6) (55) (148) (178) (190) (187) (159) (3) (171) (163) n/m
Balance, $m
Balance, $m Working capital 0 (1) 212 372 484 292 213 255 265 104 (65) n/m
Net debt 0 6 (229) (371) (337) (143) (36) (87) (97) 62 (21) n/m
Shareholders’ equity — (7) (120) 352 321 121 12 63 29 (123) (94) +43.4%
Returns, %
Returns, % ROA (37.30) (3,043.15) (122.54) (54.14) (50.38) (53.00) (74.46) (61.54) (18.03) (69.89) (78.81) (32.6) pt
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0 pt
ROE 2.38 193.87 231.57 (155.16) (72.30) (105.85) (343.53) (480.50) (122.54) 365.33 178.72 +363.0 pt
People
People Employees — 105 119 171 196 185 178 135 145 162 — +5.6%
Revenue/emp, $m — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.79 0.30 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

Gossamer Bio, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
CGTX Cognition Therapeutics, Inc. $60.4M — (loss-making) — — n/m +45.35% (above 0%: growing) 0.00% 0.00% Compare
SPRO Spero Therapeutics, Inc. $59.4M 7.4× — (loss-making) −95.61% (below 0%: shrinking) n/m +69.73% (above 0%: growing) 100.00% 0.00% Compare
CRDF Cardiff Oncology, Inc. $58.8M — (loss-making) — (loss-making) −14.05% (below 0%: shrinking) n/m −41.36% (below 0%: shrinking) 100.00% (9,245.19%) Compare
GOSS Gossamer Bio, Inc. $57.6M — (loss-making) — (loss-making) −19.59% (below 0%: shrinking) n/m +16.32% (above 0%: growing) 100.00% (282.25%)
TELO Telomir Pharmaceuticals, Inc. $57.5M — (loss-making) — — n/m −45.34% (below 0%: shrinking) — 0.00% Compare
XBIT XBiotech Inc. $57.0M — (loss-making) — (loss-making) −93.33% (below 0%: shrinking) n/m +25.25% (above 0%: growing) 0.00% 0.00% Compare
CLNN Clene Inc. $56.4M — (loss-making) — (loss-making) +273.33% (above 0%: growing) n/m −16.61% (below 0%: shrinking) 71.43% (11,333.93%) Compare
XLO Xilio Therapeutics, Inc. $55.9M — (loss-making) — (loss-making) +131.22% (above 0%: growing) n/m −26.23% (below 0%: shrinking) 100.00% (18.68%) Compare
CRBP Corbus Pharmaceuticals Holdings, Inc. $55.3M — (loss-making) — (loss-making) −92.09% (below 0%: shrinking) n/m −78.52% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $57.2M — — −53.07% — −21.42% 71.43% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 16 September 2026

Ownership

Directors and executive officers, together 4.15%
Context Funds 9.99%
683 Capital Partners, LP 9.99%
DCIG Capital Master Fund LP 7.70%
Wolverine 7.14%
D.E. Shaw Valence Portfolios, L.L.C. and D.E. Shaw Cogence Portfolios, L.L.C. 6.00%
Opaleye Management Inc. 5.10%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Gossamer Bio, Inc. (GOSS) Latest News

16 Oct

Impact 4 · · Simply Wall St.

1 Oct

Impact 4 · · Simply Wall St.

23 Sep

Impact 4 · · Business Wire

11 Sep

Impact 3 ·

27 Aug

Impact 3 ·

24 Aug

Impact 4 · · pharmaceutical-technology.com

21 Aug

Impact 4 · · InvestorsHub
Impact 4 ·
Impact 4 ·

13 Aug

Impact 3 ·

31 Jul

Impact 4 ·

28 Jul

Impact 4 ·

27 Jul

Impact 4 · · InvestorsHub
Impact 4 ·

18 Jun

Impact 3 ·

17 Jun

Impact 3 · transcript

27 May

Impact 3 · · The Motley Fool transcript

19 May

Impact 3 · · Moby transcript

18 May

Impact 4 · · Business Wire
Impact 3 · · MarketBeat transcript
Impact 3 · · Business Wire

15 May

Impact 3 ·

11 May

Impact 4 · · Simply Wall St.

23 Apr

Impact 4 · · Simply Wall St.

12 Apr

Impact 4 · · Insider Monkey

30 Mar

Impact 4 · · Insider Monkey

24 Mar

Impact 3 · · Insider Monkey

20 Mar

Impact 3 · · Insider Monkey

17 Mar

Impact 4 · · Associated Press Finance
Impact 3 · · Zacks
stockrow.com/GOSS · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com